“Dyskinesia Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Dyskinesia Market.
The Dyskinesia Pipeline report embraces in-depth commercial, regulatory, and Dyskinesia clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Dyskinesia drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Dyskinesia Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for Dyskinesia treatment and the aggregate therapies developed by major pharma companies.
It accesses the different Dyskinesia therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the major Dyskinesia companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the Dyskinesia drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Dyskinesia therapeutic market.
Dyskinesia Therapeutics Landscape
There are approx. 40+ key companies developing therapies for Dyskinesia. Currently, Contera Pharma is leading the therapeutics market with its Dyskinesia drug candidates in the most advanced stage of clinical development.
Dyskinesia Companies Actively Working in the Therapeutic Market Include:
Contera Pharma
VistaGen Therapeutics, Inc.
Neurolixis
Celon Pharma
Addex Therapeutics
IRLAB Therapeutics AB
MAPLIGHT THERAPEUTICS
Melior Pharmaceuticals
Molomics
PharmaTher
Integrative Research Laboratories AB
Teva Branded Pharmaceutical
Luye Pharma Group
IMAC holdings
Neurocrine Biosciences, Inc.
PolyCore
SOM Biotech
And Many Other
Emerging and Marketed Dyskinesia Drugs Covered in the Report Include:
JM-010: Contera Pharma
NLX 112: Neurolixis
CPL 500036: Celon Pharma
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Dyskinesia Companies Working in the Market @
https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight
Analysis of Emerging Dyskinesia Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Dyskinesia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
Oligonucleotide
Peptide
Small molecule
Learn How the Dyskinesia Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Dyskinesia Treatment Patterns
4. Dyskinesia – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Dyskinesia Late Stage Products (Phase-III)
7. Dyskinesia Mid-Stage Products (Phase-II)
8. Dyskinesia Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Dyskinesia Discontinued Products
13. Dyskinesia Product Profiles
14. Major Dyskinesia Companies in the Market
15. Key Products in the Dyskinesia Therapeutics Segment
16. Dormant and Discontinued Products
17. Dyskinesia Unmet Needs
18. Dyskinesia Future Perspectives
19. Dyskinesia Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Opioid-related Disorders Market
“Opioid-related Disorders Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Opioid-related Disorders market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Opioid-related Disorders market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailAddress:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/market-research
